$DCGO

DocGo Secures Up To $102M Term Loans at SOFR+7.5%, Issues 4M Warrants; Terminates Citi Revolver

DocGo secured up to $102M in term loans at SOFR+7.5% maturing in 2029, issued 4M warrants at $0.5039, and terminated an undrawn Citibank revolver. The financing aims to boost liquidity and support operations, including potential mergers, according to the company.

Original reporting
Published Oct 5, 2026, 10:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 10:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DocGo Secures Up To $102M Term Loans at SOFR+7.5%, Issues 4M Warrants; Terminates Citi Revolver — source image
Decision brief

The 30-second read

$DCGOBullishMed
01

Why it matters

The amendment provides $102M in term loans, a $25M delayed draw, and a warrant issuance, enhancing balance‑sheet flexibility.

02

Market read

A material capital raise for a micro‑cap, likely to affect short‑term price dynamics and investor sentiment.

03

What to watch

Potential dilution from the 4M warrants and the reliance on Perceptive Credit Holdings as a major creditor.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

DocGo Inc. (DCGO) is a publicly traded logistics platform that previously held an undrawn 2025 Citi revolver.

Company-level read

Ticker impact

$DCGOBullishHigh confidence
Context

DocGo announced a $102M term loan facility with warrants, replacing its undrawn revolving credit line.

Expected impact

potential modest upside as market prices in enhanced liquidity and reduced debt risk

Evidence & confidence

Capital raise of over $100M is material for a micro‑cap; the terms are favorable and the facility replaces a dormant revolver, reducing covenant risk.

Market effects

May signal increased financing activity in the specialty logistics/transport sector.

Limited to U.S. micro‑cap investors; no broader regional effect.

Low global relevance beyond niche investors.

Counterpoint

The high interest margin (SOFR+7.5%) could pressure cash flow if rates rise, offsetting liquidity benefits.

Key entities

  • Perceptive Credit Holdings IV

    Administrative agent and warrant holder for the new credit facility.

  • Citibank

    Provider of the terminated undrawn revolving credit facility.

Related articles

Med

DocGo Inc. Q2 2026 Earnings Call Summary

DocGo Inc. reported Q2 2026 earnings, highlighting a 19% year-over-year revenue increase in core business lines, despite a $6.3M adjusted EBITDA loss. The company announced its largest acquisition, Hicuity Health, aiming to integrate hospital and home care. Management expects to achieve positive adjusted EBITDA by year-end 2026, with revenue guidance narrowed to $305M-$310M. Cost synergies and efficiency programs are expected to drive future growth.

$DCGOMed

DocGo Shares Tumble After Earnings Miss and Wider Loss Forecast

DocGo (DCGO) shares fell 12.7% pre-market Tuesday after Q2 2026 earnings missed estimates, with a $0.16 loss per share vs. expected $0.10. Revenue was $73.4M, down 8.7% YoY, and the company widened its full-year adjusted EBITDA loss forecast to $17M-$22M. The decline followed the end of migrant-related contracts, though core revenue grew 19%. The stock trades near its 52-week low of $0.451.

$DCGOMed

DocGo Q2 Earnings Call Highlights

DocGo reported record service volumes in Q2, with year-over-year growth across all core businesses. The company acquired Hicuity, assuming $52M in debt and issuing 2% equity. DocGo's revenue rose to $52M in medical transportation but fell in mobile health due to migrant-related work decline. Adjusted EBITDA loss narrowed to $6.3M. The company updated its full-year outlook, expecting a wider EBITDA loss of $17M-$22M. DocGo has $48.1M in cash and expects positive adjusted EBITDA run rate by year-e

$DCGOMed

DocGo Inc (DCGO) (Q2 2026) Earnings Call Highlights: Record Volumes and Strategic

DocGo Inc (DCGO) reported Q2 2026 revenue of $73.4M, down from $80.4M YoY, and widened its adjusted EBITDA loss guidance to $17M-$22M. Gross margins declined due to lower margins in the Mobile Health segment and higher fuel costs. The company's cash position decreased to $48.1M. The Hicuity acquisition faces regulatory and customer approval hurdles. Organic revenue grew approximately 5% YoY. The company aims to achieve adjusted EBITDA breakeven by the end of 2026 through revenue growth, improved

$DCGOHighAI 9/10

Why is DocGo stock tumbling today?

DocGo (DCGO) shares fell 12.7% pre-open to $0.62 after its Q2 2026 adjusted loss was $0.16 per share versus $0.10 consensus. Revenue was $73.4M, below $75.4M forecast and down 8.7% YoY, tied to wind-down of migrant contracts. It widened FY2026 adjusted EBITDA loss to $17M-$22M and agreed to acquire Hicuity Health (~$65M trailing revenue).